https://www.zonebourse.com/cours/action/BIOGEN-INC-4853/actualite/Alzheimer-Biogen-obtient-l-evaluation-prioritaire-au-Japon-pour-son-lecanemab-42846820/?utm_source=telegram&utm_medium=social&utm_campaign=share